echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Pfizer stopped the production of biosimilars in China, and the former "golden track" no longer exists?

    Pfizer stopped the production of biosimilars in China, and the former "golden track" no longer exists?

    • Last Update: 2021-07-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


















    On February 18, CDE issued the Technical Guidelines for the Evaluation of Similarity of Biologicalsimilars and the Extrapolation of Indications
    .
    In this regard, industry insiders commented: The "consistency evaluation" of biosimilar drugs is coming and will also be included in centralized procurement in the future
    .


    Previously, biopharmaceuticals were once known as the "forbidden zone for volume procurement", which could avoid the price impact of centralized procurement
    .
    In addition, the research and development cost of biosimilar drugs is lower than that of original innovative drugs, and many domestic and foreign companies are more enthusiastic about biosimilar drugs
    .


    Now that the "forbidden zone" is broken, this will naturally bring down the enthusiasm of the company
    .


    As far as adalimumab is concerned, the original price of the original research drug Xiu Meile is 7586 yuan/piece (40ml), the medical insurance payment price is 1,290 yuan/piece, and Biotech’s Gelli is priced at 1,160 yuan/piece, and Hisun Pharmaceuticals The price of An Jianning and Cinda Bio's Su Lixin are both 1150 yuan/piece
    .
    The Handa of Fuhong Hanli is far 899 yuan/piece
    .


    If we refer to the 75% average drop in the centralized procurement of chemical drugs, the price of biosimilar drugs after the centralized procurement is expected to drop to less than 1,000 yuan
    .
    This is undoubtedly a head-on blow to companies including Pfizer that have not yet entered the market
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.